Gateway Investment Advisers LLC Has $550,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Gateway Investment Advisers LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 1.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,282 shares of the medical instruments supplier’s stock after selling 45 shares during the period. Gateway Investment Advisers LLC’s holdings in Becton, Dickinson and Company were worth $550,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC lifted its stake in shares of Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC grew its holdings in shares of Becton, Dickinson and Company by 2,086.7% in the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $11,998,000. Avity Investment Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after acquiring an additional 5,527 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Becton, Dickinson and Company by 9.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock worth $14,481,000 after purchasing an additional 5,006 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $236.50 on Monday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $262.55. The firm has a market capitalization of $68.35 billion, a P/E ratio of 52.09, a P/E/G ratio of 1.79 and a beta of 0.42. The firm’s 50-day moving average price is $236.37 and its 200-day moving average price is $235.30.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the prior year, the business posted $2.96 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.